Cite
HARVARD Citation
Alping, P. et al. (2020). Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of neurology. 87 (5), pp. 688-699. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Alping, P. et al. (2020). Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of neurology. 87 (5), pp. 688-699. [Online].